Study of SYN608 for advanced solid tumors
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called SYN608 for people with advanced breast, ovarian, or other solid tumors that have stopped responding to standard treatments. It looks for a specific genetic change (BRCA mutation or related DNA repair problem) to see if the drug might work better for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced breast, ovarian, or another solid tumor that has gotten worse after standard treatments.
- You are willing to provide a tumor sample or blood sample to check for a BRCA mutation or related DNA repair issue.
- You must have at least one tumor that can be measured on a scan.
- You are 18 or older and in reasonably good health (able to care for yourself).
- You have not taken a similar drug called a PARG inhibitor before.
- You do not have active or uncontrolled brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).
This trial tests a new study drug (SYS6043) for people with advanced or metastatic solid tumors that have not responded to or are not candidates for standard therapies. The drug targets a protein called B7-H3 on cancer cells to help stop tumor growth.
This clinical trial tests a new investigational drug (SYS6010) combined with another drug (SYH2051) or given alone, compared to standard chemotherapy, for advanced breast cancer and other solid tumors that have a specific protein called EGFR. The goal is to see if this treatment can help shrink tumors or slow their growth.
This trial tests a new drug called SYS6041 for people with certain advanced cancers that have not responded to standard treatments. It targets a protein called FRα found on some tumor cells, which may help the drug attack the cancer more effectively.
This trial tests a new drug, HRS-6209, combined with different hormone treatments (fulvestrant, letrozole, HRS-8080, or HRS-1358) for people with advanced breast cancer that has spread or cannot be surgically removed and has worsened after previous treatments.
Hear when a new Advanced Solid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.